The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [11]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Shah, S. P., Köbel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., Leung, G., Zayed, A., Mehl, E., Kalloger, S. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902542 · Cited by 768
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Cited by
Items 201–300 of 1,006
Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy
Xia, X., Yang, Z., Lu, Q., Liu, Z., Wang, L., Du, J., Li, Y., Yang, D., & Wu, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02079-8 · Cited by 128
Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15
Ting, T. C., Goralski, M., Klein, K., Wang, B., Kim, J., Xie, Y., & Nijhawan, D. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.079 · Cited by 123
Shirasaki, R., Matthews, G. M., Gandolfi, S., de Matos Simoes, R., Buckley, D. L., Raja Vora, J., Sievers, Q. L., Brüggenthies, J. B., Dashevsky, O., Poarch, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108532 · Cited by 123
Self-citationStrategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 108
Mayor-Ruiz, C., Jaeger, M. G., Bauer, S., Brand, M., Sin, C., Hanzl, A., Mueller, A. C., Menche, J., & Winter, G. E. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.013 · Cited by 119
Bellinger, A. M., Arteaga, C. L., Force, T., Humphreys, B. D., Demetri, G. D., Druker, B. J., & Moslehi, J. J. (2015) · Circulation · doi:10.1161/circulationaha.115.010484 · Cited by 117
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma
Seong, B. K. A., Dharia, N. V., Lin, S., Donovan, K. A., Chong, S., Robichaud, A., Conway, A., Hamze, A., Ross, L., Alexe, G., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.003 · Cited by 113
Schröder, M., Renatus, M., Liang, X., Meili, F., Zoller, T., Ferrand, S., Gauter, F., Li, X., Sigoillot, F., Gleim, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44237-4 · Cited by 97
Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders
Lu, P., Cheng, Y., Xue, L., Ren, X., Xu, X., Chen, C., Cao, L., Li, J., Wu, Q., Sun, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.015 · Cited by 125
Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition
Petzold, G., Gainza, P., Annunziato, S., Lamberto, I., Trenh, P., McAllister, L. A., DeMarco, B., Schwander, L., Bunker, R. D., Zlotosch, M., et al. (2025) · Science · doi:10.1126/science.adt6736 · Cited by 117
Protein Degradation and the Pathologic Basis of Disease
Hanna, J., Guerra-Moreno, A., Ang, J., & Micoogullari, Y. (2019) · The American Journal of Pathology · doi:10.1016/j.ajpath.2018.09.004 · Cited by 111
Role of the tumor microenvironment in mature B-cell lymphoid malignancies
Fowler, N. H., Cheah, C. Y., Gascoyne, R. D., Gribben, J. G., Neelapu, S. S., Ghia, P., Bollard, C. M., Ansell, S., Curran, M. A., Wilson, W. H., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139493 · Cited by 121
Targeting the undruggables—the power of protein degraders
Zhang, C., Liu, Y., Li, G., Yang, Z., Han, C., Sun, X., Sheng, C., Ding, K., & Rao, Y. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.03.056 · Cited by 118
Gopalakrishnan, R., Matta, H., Tolani, B., Triche Jr, T., & Chaudhary, P. M. (2016) · Oncogene · doi:10.1038/onc.2015.245 · Cited by 112
Targeted protein knockdown using small molecule degraders
Raina, K., & Crews, C. M. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.05.016 · Cited by 110
Distinct and overlapping functions of the cullin E3 ligase scaffolding proteins CUL4A and CUL4B
Hannah, J., & Zhou, P. (2015) · Gene · doi:10.1016/j.gene.2015.08.064 · Cited by 110
Molecular glues and bifunctional compounds: Therapeutic modalities based on induced proximity
Schreiber, S. L. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.05.004 · Cited by 112
Gherardin, N. A., Loh, L., Admojo, L., Davenport, A. J., Richardson, K., Rogers, A. J., Darcy, P. K., Jenkins, M. R., Prince, H. M., Harrison, S. J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22130-1 · Cited by 111
Novel therapeutic strategies for multiple myeloma
Mimura, N., Hideshima, T., & Anderson, K. C. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.04.010 · Cited by 120
Snyder, L. B., Neklesa, T. K., Willard, R. R., Gordon, D., Pizzano, J., Vitale, N., Robling, K., Dorso, M. A., Moghrabi, W. N., Landrette, S. F., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0655 · Cited by 114
Disruption of IRE1α through its kinase domain attenuates multiple myeloma
Harnoss, J. M., Le Thomas, A., Shemorry, A., Marsters, S. A., Lawrence, D. A., Lu, M., Chen, Y.-C. A., Qing, J., Totpal, K., Kan, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906999116 · Cited by 109
Toumishey, E., Prasad, A., Dueck, G., Chua, N. S., Finch, D. L., Johnston, J. B., van der Jagt, R., Stewart, D., White, D. J., Belch, A. R., et al. (2014) · Cancer · doi:10.1002/cncr.29103 · Cited by 111
Phthalimide conjugations for the degradation of oncogenic PI3K
Li, W., Gao, C., Zhao, L., Yuan, Z., Chen, Y., & Jiang, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.066 · Cited by 109
Target protein localization and its impact on PROTAC-mediated degradation
Simpson, L. M., Glennie, L., Brewer, A., Zhao, J., Crooks, J., Shpiro, N., & Sapkota, G. P. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.004 · Cited by 114
Cereblon modulators: Low molecular weight inducers of protein degradation
Chamberlain, P. P., & Cathers, B. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.004 · Cited by 106
Zhu, Y. X., Shi, C.-X., Bruins, L. A., Wang, X., Riggs, D. L., Porter, B., Ahmann, J. M., de Campos, C. B., Braggio, E., Bergsagel, P. L., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0173-0 · Cited by 100
Lin, X., Xiang, H., & Luo, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112689 · Cited by 94
Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex
Matyskiela, M. E., Clayton, T., Zheng, X., Mayne, C., Tran, E., Carpenter, A., Pagarigan, B., McDonald, J., Rolfe, M., Hamann, L. G., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0405-9 · Cited by 103
Self-citationDulmovits, B. M., Appiah-Kubi, A. O., Papoin, J., Hale, J., He, M., Al-Abed, Y., Didier, S., Gould, M., Husain-Krautter, S., Singh, S. A., et al. (2016) · Blood · doi:10.1182/blood-2015-09-667923 · Cited by 99
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review
Li, W., Garcia, D. A., Cornell, R. F., Gailani, D., Laubach, J. P., Maglio, M. E., Richardson, P. G. G., & Moslehi, J. J. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3350 · Cited by 109
Lenalidomide induces degradation of IKZF1 and IKZF3
Krönke, J., Hurst, S. N., & Ebert, B. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.941742 · Cited by 95
Targeting Ubiquitination for Cancer Therapies
Morrow, J. K., Lin, H., Sun, S., & Zhang, S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.148 · Cited by 110
Gao, J., Mfuh, A., Amako, Y., & Woo, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11639 · Cited by 102
Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00290-3 · Cited by 101
PROTAC-mediated crosstalk between E3 ligases
Steinebach, C., Kehm, H., Lindner, S., Vu, L. P., Köpff, S., López Mármol, Á., Weiler, C., Wagner, K. G., Reichenzeller, M., Krönke, J., et al. (2019) · Chemical Communications · doi:10.1039/c8cc09541h · Cited by 97
Bifunctional chemical probes inducing protein–protein interactions
Maniaci, C., & Ciulli, A. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.07.003 · Cited by 100
A covalently bound inhibitor triggers EZH2 degradation through CHIP‐mediated ubiquitination
Wang, X., Cao, W., Zhang, J., Yan, M., Xu, Q., Wu, X., Wan, L., Zhang, Z., Zhang, C., Qin, X., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201694058 · Cited by 102
Pech, M. F., Fong, L. E., Villalta, J. E., Chan, L. J., Kharbanda, S., O’Brien, J. J., McAllister, F. E., Firestone, A. J., Jan, C. H., & Settleman, J. E. (2019) · eLife · doi:10.7554/elife.47362 · Cited by 104
Ahn, G., Banik, S. M., & Bertozzi, C. R. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.02.024 · Cited by 93
Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia
Garnar-Wortzel, L., Bishop, T. R., Kitamura, S., Milosevich, N., Asiaban, J. N., Zhang, X., Zheng, Q., Chen, E., Ramos, A. R., Ackerman, C. J., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01550 · Cited by 100
Epigenetic regulation of fetal globin gene expression in adult erythroid cells
Ginder, G. D. (2014) · Translational research · doi:10.1016/j.trsl.2014.05.002 · Cited by 105
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
Neurofibromin and suppression of tumorigenesis: beyond the GAP
Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022) · Oncogene · doi:10.1038/s41388-021-02156-y · Cited by 100
A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction
Ting, P. Y., Borikar, S., Kerrigan, J. R., Thomsen, N. M., Aghania, E., Hinman, A. E., Reyes, A., Pizzato, N., Fodor, B. D., Wu, F., et al. (2024) · Science · doi:10.1126/science.adk6129 · Cited by 97
Self-citationMultiple Myeloma Therapy: Emerging Trends and Challenges
Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H., Ullah, F., Khouri, J., Maciejewski, J. P., & Jha, B. K. (2022) · Cancers · doi:10.3390/cancers14174082 · Cited by 101
Abruzzese, M. P., Bilotta, M. T., Fionda, C., Zingoni, A., Soriani, A., Vulpis, E., Borrelli, C., Zitti, B., Petrucci, M. T., Ricciardi, M. R., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0362-2 · Cited by 94
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
de Waal, L., Lewis, T. A., Rees, M. G., Tsherniak, A., Wu, X., Choi, P. S., Gechijian, L., Hartigan, C., Faloon, P. W., Hickey, M. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1984 · Cited by 96
“The dependence of DNMDP cytotoxicity on PDE3A protein abundance suggests a possible mechanism similar to that recently observed for lenalidomide, which acts by a neomorphic or hypermorphic mechanism by stabilizing an interaction between cereblon and IKZF1 and IKZF3 16,17 .”
BackgroundNovel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95
Targeting the Ubiquitin–Proteasome System and Recent Advances in Cancer Therapy
Spano, D., & Catara, G. (2023) · Cells · doi:10.3390/cells13010029 · Cited by 98
CRL4ACRBN E3 ubiquitin ligase restricts BK channel activity and prevents epileptogenesis
Liu, J., Ye, J., Zou, X., Xu, Z., Feng, Y., Zou, X., Chen, Z., Li, Y., & Cang, Y. (2014) · Nature Communications · doi:10.1038/ncomms4924 · Cited by 99
An overview of kinase downregulators and recent advances in discovery approaches
Wang, B., Wu, H., Hu, C., Wang, H., Liu, J., Wang, W., & Liu, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00826-7 · Cited by 100
Ocio, E. M., Fernández-Lázaro, D., San-Segundo, L., López-Corral, L., Corchete, L. A., Gutiérrez, N. C., Garayoa, M., Paíno, T., García-Gómez, A., Delgado, M., et al. (2015) · Leukemia · doi:10.1038/leu.2014.238 · Cited by 87
IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
Fedele, P. L., Willis, S. N., Liao, Y., Low, M. S. Y., Rautela, J., Segal, D., Gong, J., Huntington, N. D., Shi, W., Huang, D. C. S., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850727 · Cited by 95
Lucas, X., & Ciulli, A. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.12.015 · Cited by 101
Fionda, C., Abruzzese, M. P., Zingoni, A., Cecere, F., Vulpis, E., Peruzzi, G., Soriani, A., Molfetta, R., Paolini, R., Ricciardi, M. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4603 · Cited by 95
Mazzurana, L., Forkel, M., Rao, A., Acker, A. V., Kokkinou, E., Ichiya, T., Almer, S. H., Höög, C., Friberg, D., & Mjösberg, J. (2019) · European Journal of Immunology · doi:10.1002/eji.201848075 · Cited by 94
ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells
Yamamoto, J., Suwa, T., Murase, Y., Tateno, S., Mizutome, H., Asatsuma‐Okumura, T., Shimizu, N., Kishi, T., Momose, S., Kizaki, M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0645-3 · Cited by 98
Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System
Abbas, R., & Larisch, S. (2021) · Cells · doi:10.3390/cells10123465 · Cited by 95
Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation
Sun, D., Zhang, J., Dong, G., He, S., & Sheng, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01159 · Cited by 91
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Gao, J., Yang, L., Lei, S., Zhou, F., Nie, H., Peng, B., Xu, T., Chen, X., Yang, X., Sheng, C., et al. (2023) · Science Bulletin · doi:10.1016/j.scib.2023.04.028 · Cited by 87
Gao, H., Xi, Z., Dai, J., Xue, J., Guan, X., Zhao, L., Chen, Z., & Xing, F. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02005-y · Cited by 92
Dimopoulos, K., Søgaard Helbo, A., Fibiger Munch‐Petersen, H., Sjö, L., Christensen, J., Sommer Kristensen, L., Asmar, F., Hermansen, N. E. U., O'Connel, C., Gimsing, P., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12157 · Cited by 87
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Sulahian, R., Kwon, J. J., Walsh, K. H., Pailler, E., Bosse, T. L., Thaker, M., Almanza, D., Dempster, J. M., Pan, J., Piccioni, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.090 · Cited by 90
Rui, H., Ashton, K. S., Min, J., Wang, C. W., & Potts, P. R. (2023) · RSC Chemical Biology · doi:10.1039/d2cb00207h · Cited by 94
Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
Furihata, H., Yamanaka, S., Honda, T., Miyauchi, Y., Asano, A., Shibata, N., Tanokura, M., Sawasaki, T., & Miyakawa, T. (2020) · Nature Communications · doi:10.1038/s41467-020-18488-4 · Cited by 89
Yamanaka, S., Murai, H., Saito, D., Abe, G., Tokunaga, E., Iwasaki, T., Takahashi, H., Takeda, H., Suzuki, T., Shibata, N., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020105375 · Cited by 89
“These include IKZF1 (Kr € onke et al , 2014; Lu et al , 2014), IKZF3 (Kr € onke et al , 2014; Lu et al , 2014) and SALL4 (Donovan et al , 2018; Matyskiela et al , 2018).”
InfluentialSmall-Molecule Targeting of BET Proteins in Cancer
French, C. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.04.001 · Cited by 92
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 85
Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0193 · Cited by 88
“Briefly, 50 mL of Dual-Glo luciferase buffer (16) was added to wells and incubated for 30 minutes at room temperature before analysis of firefly luminescence.”
MethodA Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders
Millrine, D., & Kishimoto, T. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.02.006 · Cited by 97
Molecular Mechanisms of the Teratogenic Effects of Thalidomide
Asatsuma‐Okumura, T., Ito, T., & Handa, H. (2020) · Pharmaceuticals · doi:10.3390/ph13050095 · Cited by 90
Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library
Powell, C. E., Du, G., Che, J., He, Z., Donovan, K. A., Yue, H., Wang, E. S., Nowak, R. P., Zhang, T., Fischer, E. S., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00520 · Cited by 84
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 92
Fecteau, J.-F., Corral, L. G., Ghia, E. M., Gaidarova, S., Futalan, D., Bharati, I. S., Cathers, B. E., Schwaederle, M. C., Cui, B., Lopez‐Girona, A., et al. (2014) · Blood · doi:10.1182/blood-2014-03-559591 · Cited by 93
Promising therapies in multiple myeloma
Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood · doi:10.1182/blood-2015-03-575365 · Cited by 93
Ikaros family zinc finger 1 regulates dendritic cell development and function in humans
Cytlak, U., Resteu, A., Bogaert, D., Kuehn, H. S., Altmann, T., Gennery, A., Jackson, G., Kumanovics, A., Voelkerding, K. V., Prader, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02977-8 · Cited by 81
Superenhancer reprogramming drives a B-cell–epithelial transition and high-risk leukemia
Hu, Y., Zhang, Z., Kashiwagi, M., Yoshida, T., Joshi, I., Jena, N., Somasundaram, R., Emmanuel, A. O., Sigvardsson, M., Fitamant, J., et al. (2016) · Genes & Development · doi:10.1101/gad.283762.116 · Cited by 87
Ikaros fingers on lymphocyte differentiation
Yoshida, T., & Georgopoulos, K. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1644-5 · Cited by 86
ZNF410 represses fetal globin by singular control of CHD4
Vinjamur, D. S., Yao, Q., Cole, M. A., McGuckin, C., Ren, C., Zeng, J., Hossain, M. A., Luk, K., Wolfe, S. A., Pinello, L., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00843-w · Cited by 89
p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates
Nguyen, T. V., Li, J., Lu, C.-C. (., Mamrosh, J. L., Lu, G., Cathers, B. E., & Deshaies, R. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700949114 · Cited by 85
Self-citationUsing Ubiquitin Binders to Decipher the Ubiquitin Code
Mattern, M. R., Sutherland, J. D., Kadimisetty, K., Barrio, R., & Rodríguez, M. S. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.01.011 · Cited by 85
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies
Bianchi, G., Zhang, Y., & Comenzo, R. L. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.09.003 · Cited by 92
Continuous evolution of compact protein degradation tags regulated by selective molecular glues
Mercer, J. A. M., DeCarlo, S. J., Roy Burman, S. S., Sreekanth, V., Nelson, A. T., Hunkeler, M., Chen, P. J., Donovan, K. A., Kokkonda, P., Tiwari, P. K., et al. (2024) · Science · doi:10.1126/science.adk4422 · Cited by 82
Unveiling the hidden interactome of CRBN molecular glues
Baek, K., Metivier, R. J., Roy Burman, S. S., Bushman, J. W., Yoon, H., Lumpkin, R. J., Ryan, J. K., Abeja, D. M., Lakshminarayan, M., Yue, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62099-w · Cited by 61
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84
Targeting chromatin complexes in fusion protein-driven malignancies
Brien, G. L., Stegmaier, K., & Armstrong, S. A. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0132-x · Cited by 86
Chemical strategies to overcome resistance against targeted anticancer therapeutics
Pisa, R., & Kapoor, T. M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0596-8 · Cited by 86
Yamanaka, S., Horiuchi, Y., Matsuoka, S., Kido, K., Nishino, K., Maeno, M., Shibata, N., Kosako, H., & Sawasaki, T. (2022) · Nature Communications · doi:10.1038/s41467-021-27818-z · Cited by 86
Paiva, B., Mateos, M., Sánchez‐Abarca, L. I., Puig, N., Vídriales, M., López‐Corral, L., Corchete, L. A., Hernández, M., Bargay, J., de Arriba, F., et al. (2015) · Blood · doi:10.1182/blood-2015-10-662320 · Cited by 90
Liu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0205-y · Cited by 83
Fang, J., Liu, X., Bolanos, L., Barker, B., Rigolino, C., Cortelezzi, A., Oliva, E. N., Cuzzola, M., Grimes, H. L., Fontanillo, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4127 · Cited by 83
DNA-encoded library-enabled discovery of proximity-inducing small molecules
Mason, J. W., Chow, Y. T., Hudson, L., Tutter, A., Michaud, G., Westphal, M. V., Shu, W., Ma, X., Tan, Z. Y., Coley, C. W., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01458-4 · Cited by 83
Yang, K., Zhao, Y., Nie, X., Wu, H., Wang, B., Almodóvar‐Rivera, C. M., Xie, H., & Tang, W. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.04.008 · Cited by 85
Regulation of cell cycle drivers by Cullin-RING ubiquitin ligases
Jang, S., Redon, C. E., Thakur, B. L., Bahta, M., & Aladjem, M. I. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00508-4 · Cited by 87
Photoreceptor nanotubes mediate the in vivo exchange of intracellular material
Ortín-Martínez, A., Yan, N. E., Tsai, E. L. S., Comanita, L., Gurdita, A., Tachibana, N., Liu, Z. C., Lü, S., Dolati, P., Pokrajac, N. T., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020107264 · Cited by 82
Hoshino, A., Boutboul, D., Zhang, Y., Kuehn, H. S., Hadjadj, J., Özdemir, N., Celkan, T. T., Walz, C., Pïcard, C., Lenoir, C., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abi7160 · Cited by 83
Viswanathan, S. R., Nogueira, M. F., Buss, C. G., Krill-Burger, J. M., Wawer, M. J., Małolepsza, E., Berger, A. C., Choi, P. S., Shih, J., Taylor, A. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0155-3 · Cited by 88
Molecular mechanisms of cereblon-based drugs
Asatsuma‐Okumura, T., Ito, T., & Handa, H. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.004 · Cited by 89
Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)
Xie, S., Sun, Y., Liu, Y., Li, X., Li, X., Zhong, W., Zhan, F., Zhu, J., Yao, H., Yang, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00270 · Cited by 81
Siu, K. T., Ramachandran, J., Yee, A. J., Eda, H., Santo, L., Panaroni, C., Mertz, J. A., Sims, R. J., Cooper, M. R., & Raje, N. S. (2016) · Leukemia · doi:10.1038/leu.2016.355 · Cited by 84
Metadata
- Authors
- Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 305-309
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4070318
- OpenAlex
- W2068412287
- Semantic Scholar
- 78bec298ec2a26703ac77b2d1a6e38c4778689df
- Cited by
- 1,583
- References
- 35
- Citations by year
- 2026: 113 · 2025: 123 · 2024: 152 · 2023: 136 · 2022: 149 · 2021: 179 · 2020: 167 · 2019: 111 · 2018: 120 · 2017: 93 · 2016: 88 · 2015: 85 · 2014: 63
- FWCI
- 35.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA076120)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, cereblon, IKZF1, IKZF3, multiple myeloma, ubiquitin ligase, proteasomal degradation, teratogenicity, zebrafish, anticancer mechanism
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Multiple Myeloma, Peptide Hydrolases, Teratogens, Thalidomide, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Ikaros Transcription Factor, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.